Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)

Cellusion Director and Executive Appointments

Cellusion and Minaris Regenerative Medicine, a Member of Showa Denko Materials, Enter into Business Alliance for CLS001 Global Development

Dr. Hatou presented Cellusion business progress in the 2022 Cell & Gene Meeting on the Mesa

Cellusion and Celregen, a member of Fosun Pharma, Enter into License Agreement of CLS001

Cellusion moves the HQs in Nihonbashi-Kobuna Area

A joint research paper between Cellusion and Keio University published in STEM CELLS Translational Medicine.

The CLS001 FIH study infomaiton was disclosed in jRCT.

Dr. Hatou presented Cellusion business progress in the BIO International Convention.

Dr. Hatou presented Cellusion business progress in the 2022 Cell & Gene Meeting on the Med.